MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-31-2026
VolitionRx Limited Accounts Receivables 2011-2026 | VNRX
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables VolitionRx Limited
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 318 K | 111 K | 243 K | 72.6 K | 12.5 K | 7.12 K | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 318 K | 7.12 K | 127 K |
Quarterly Accounts Receivables VolitionRx Limited
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 309 K | 190 K | 188 K | 111 K | 313 K | 166 K | 134 K | 243 K | 34.4 K | 196 K | 119 K | 72.6 K | 5.49 K | 8.49 K | 72.4 K | 12.5 K | 19.6 K | 15.8 K | 14.2 K | 7.12 K | 7.12 K | 7.12 K | 7.12 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 933 | 11.7 K | 15.7 K | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 313 K | 933 | 87.7 K |
Accounts Receivables of other stocks in the Diagnostics research industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Akumin
AKU
|
114 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Burning Rock Biotech Limited
BNR
|
88.2 M | $ 16.65 | - | $ 179 M |  China |
 |
Agilent Technologies
A
|
1.17 B | $ 113.98 | -0.78 % | $ 34.6 B |  USA |
 |
Accelerate Diagnostics
AXDX
|
2.42 M | - | -61.36 % | $ 2.46 M | USA |
 |
Aspira Women's Health
AWH
|
1.21 M | - | -6.19 % | $ 10.5 M | USA |
 |
Biocept
BIOC
|
2.15 M | - | -13.05 % | $ 7.29 M | USA |
 |
Chembio Diagnostics
CEMI
|
6.54 M | - | 0.22 % | $ 16.8 M | USA |
 |
Castle Biosciences
CSTL
|
51.2 M | $ 24.15 | -2.23 % | $ 671 M | USA |
 |
Co-Diagnostics
CODX
|
190 K | $ 1.61 | -1.21 % | $ 2.14 M | USA |
 |
CareDx, Inc
CDNA
|
42.6 M | $ 22.01 | 0.43 % | $ 1.17 B | USA |
 |
DermTech
DMTK
|
2.58 M | - | -11.32 % | $ 2.94 M | USA |
 |
Enzo Biochem
ENZ
|
3.99 M | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
299 M | - | - | $ 19.8 B | USA |
 |
Fulgent Genetics
FLGT
|
69 M | $ 15.24 | -0.39 % | $ 461 M | USA |
 |
Illumina
ILMN
|
735 M | $ 125.07 | -1.46 % | $ 19.9 B | USA |
 |
Global Cord Blood Corporation
CO
|
416 M | - | - | $ 399 M | China |
 |
Charles River Laboratories International
CRL
|
709 M | $ 167.08 | 0.22 % | $ 8.28 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
1.42 M | - | -20.0 % | $ 1.06 M | USA |
 |
Guardant Health
GH
|
138 M | $ 82.63 | -0.59 % | $ 10.4 B | USA |
 |
Lantheus Holdings
LNTH
|
359 M | $ 82.9 | -0.78 % | $ 5.59 B | USA |
 |
Heska Corporation
HSKA
|
29.5 M | - | - | $ 1.31 B | USA |
 |
Interpace Biosciences
IDXG
|
5.65 M | $ 1.93 | - | $ 8.54 M | USA |
 |
Personalis
PSNL
|
8.14 M | $ 5.34 | -2.92 % | $ 316 M | USA |
 |
Senseonics Holdings
SENS
|
205 K | $ 7.03 | -2.09 % | $ 293 M | USA |
 |
QIAGEN N.V.
QGEN
|
381 M | - | - | $ 10.6 B |  Niderland |
 |
Medpace Holdings
MEDP
|
402 M | $ 403.62 | -1.5 % | $ 11.6 B | USA |
 |
Biomerica
BMRA
|
731 K | $ 2.18 | -0.46 % | $ 5.01 M | USA |
 |
Motus GI Holdings
MOTS
|
76 K | - | -34.28 % | $ 263 K |  Israel |
 |
ICON Public Limited Company
ICLR
|
1.34 B | $ 111.86 | 9.14 % | $ 9.23 B |  Irlanda |
 |
Laboratory Corporation of America Holdings
LH
|
2.1 B | $ 260.29 | 0.29 % | $ 21.7 B | USA |
 |
NeoGenomics
NEO
|
159 M | $ 9.6 | 6.43 % | $ 1.23 B | USA |
 |
Twist Bioscience Corporation
TWST
|
57 M | $ 57.42 | -2.92 % | $ 3.43 B | USA |
 |
Neogen Corporation
NEOG
|
153 M | $ 9.19 | -1.61 % | $ 1.99 B | USA |
 |
National Research Corporation
NRC
|
11.1 M | $ 15.88 | -5.7 % | $ 355 M | USA |
 |
Myriad Genetics
MYGN
|
115 M | $ 4.77 | -1.45 % | $ 442 M | USA |
 |
Natera
NTRA
|
244 M | $ 196.02 | -2.08 % | $ 19.3 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
1.41 B | $ 192.19 | -1.43 % | $ 21.3 B | USA |
 |
Invitae Corporation
NVTA
|
96.1 M | - | - | $ 21.2 M | USA |
 |
Exagen
XGN
|
10.9 M | $ 2.68 | -1.83 % | $ 57.8 M | USA |
 |
OpGen
OPGN
|
29.3 K | - | -16.95 % | $ 1.54 M | USA |